BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib

Introduction: DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expression. Olaparib was tested in combination with gefitinib versus gefitinib single a...

Full description

Bibliographic Details
Main Authors: Niki Karachaliou, MD, PhD, Oscar Arrieta, MD, Ana Giménez-Capitán, BSc, Erika Aldeguer, BSc, Ana Drozdowskyj, PhD, Imane Chaib, PhD, Noemí Reguart, MD, PhD, Rosario Garcia-Campelo, MD, Jing-Hua Chen, MD, Miguel Angel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR
Lung cancer
Gefitinib
Olaparib
GOAL study
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301594

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301594

Similar Items